Log in

NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

$35.28
-0.53 (-1.48 %)
(As of 03/29/2020 05:53 AM ET)
Today's Range
$34.04
Now: $35.28
$36.24
50-Day Range
$27.51
MA: $41.75
$54.05
52-Week Range
$26.56
Now: $35.28
$67.86
Volume617,813 shs
Average Volume1.03 million shs
Market Capitalization$2.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.6
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.
Read More
Biohaven Pharmaceutical logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.14) per share

Profitability

Net Income$-528,800,000.00

Miscellaneous

Employees63
Market Cap$2.06 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.


Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

How has Biohaven Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BHVN shares have decreased by 10.6% and is now trading at $35.28. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biohaven Pharmaceutical?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Biohaven Pharmaceutical.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings results on Tuesday, February, 25th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by $0.94. During the same period in the prior year, the company posted ($1.34) earnings per share. View Biohaven Pharmaceutical's earnings history.

What price target have analysts set for BHVN?

12 Wall Street analysts have issued twelve-month price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $70.36 in the next twelve months. This suggests a possible upside of 99.4% from the stock's current price. View analysts' price targets for Biohaven Pharmaceutical.

Has Biohaven Pharmaceutical been receiving favorable news coverage?

News articles about BHVN stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutBiohaven Pharmaceutical.

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include Alibaba Group (BABA), AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Amarin (AMRN), Baidu (BIDU) and Roku (ROKU).

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:
  • Dr. Vladimir Coric, CEO & Director (Age 48)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 57)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (5.59%), Oracle Investment Management Inc. (3.68%), State Street Corp (3.66%), Capital World Investors (3.15%), Capital International Inc. CA (2.18%) and Eagle Asset Management Inc. (1.43%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical.

Which institutional investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Oracle Investment Management Inc., Marshall Wace LLP, Eagle Asset Management Inc., Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., State Street Corp, and UBS Group AG. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, Kimberly Gentile, and Robert Berman. View insider buying and selling activity for Biohaven Pharmaceutical.

Which institutional investors are buying Biohaven Pharmaceutical stock?

BHVN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Norges Bank, Point72 Asset Management L.P., Pictet Asset Management Ltd., Bluefin Trading LLC, Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $35.28.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $2.06 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe. View additional information about Biohaven Pharmaceutical.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  633
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel